PDT Partners LLC Has $5.75 Million Stock Holdings in 10x Genomics $TXG

Key Points

• PDT Partners LLC increased its ownership in 10x Genomics by 85.7% during the 1st quarter, now holding approximately 0.54% of the company's shares valued at $5,753,000.
• Equities research analysts have mixed ratings on 10x Genomics, with Goldman Sachs lowering its price target from $7.50 to $6.50, while Deutsche Bank set a target of $14.00, marking a "hold" rating.
• The company's recent earnings report indicated an EPS of $0.28, beating expectations significantly, and revenue of $172.91 million, a 12.9% increase from the previous year.

PDT Partners LLC increased its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 85.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 659,040 shares of the company's stock after buying an additional 304,082 shares during the period. PDT Partners LLC owned 0.54% of 10x Genomics worth $5,753,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after purchasing an additional 1,614 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in 10x Genomics during the 4th quarter worth about $32,000. Signaturefd LLC raised its holdings in 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after purchasing an additional 2,409 shares during the last quarter. Whittier Trust Co. bought a new stake in 10x Genomics during the 1st quarter worth about $41,000. Finally, PNC Financial Services Group Inc. raised its holdings in 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after purchasing an additional 3,119 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

Wall Street Analyst Weigh In

TXG has been the subject of a number of recent analyst reports. Stephens reaffirmed an "overweight" rating and issued a $14.00 price target on shares of 10x Genomics in a research note on Thursday, May 15th. UBS Group increased their target price on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Barclays reaffirmed an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on 10x Genomics and gave the stock a "hold" rating in a research report on Friday, August 8th. Finally, Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $13.54.

10x Genomics Trading Up 1.7%

TXG stock traded up $0.23 during trading hours on Thursday, hitting $13.57. 1,709,156 shares of the stock were exchanged, compared to its average volume of 3,359,604. The firm has a market capitalization of $1.69 billion, a P/E ratio of -19.39 and a beta of 2.00. The company has a 50-day simple moving average of $13.07 and a two-hundred day simple moving average of $10.73. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to analysts' expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company's quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, equities research analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Adam Taich sold 22,315 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. This trade represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,149 shares of company stock worth $539,865. Company insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.